May 7, 2021 - Contract Pharma
Catalent has acquired Promethera Biosciences’ cell therapy manufacturing subsidiary Hepatic Cell Therapy Support—the fourth company to join Catalent’s swiftly growing cell and gene therapy campus in Gosselies, Belgium. As part of the deal, Catalent will get its hands on HCTS’ 32,400-square-foot plant there, located right alongside the Delphi Genetics facility Catalent picked up earlier this year.
May 6, 2021 - Fierce Pharma
Catalent has acquired Promethera Biosciences’ cell therapy manufacturing subsidiary Hepatic Cell Therapy Support—the fourth company to join Catalent’s swiftly growing cell and gene therapy campus in Gosselies, Belgium. As part of the deal, Catalent will get its hands on HCTS’ 32,400-square-foot plant there, located right alongside the Delphi Genetics facility Catalent picked up earlier this year.
May 5, 2021 - Fierce Healthcare
R1, a publicly-traded company, intends to fund the transaction with a combination of cash from its balance sheet and debt. The transaction provides a tax benefit valued at approximately $40 million, equating to an effective purchase price of approximately $260 million, the company said in a press release issued Tuesday.
May 5, 2021 - Contract Pharma
Contract Pharma spoke with GlobalData’s Peter Shapiro, senior director of drugs and business fundamentals, about the trends he is seeing in the contract services space in the U.S., Europe and Asia. Shapiro discusses how the many recent large COVID contracts have benefited the industry and looks ahead at what the implications might be over the next few years. He explores growth areas like cell and gene therapies, mRNA and vaccines, as well as geopolitical factors and how development capacity constraints are helping drive increased venture capital (VC) interest.
